Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | SOAT1 | P35610 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | GPX4 | P36969 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.44 |
| ▸ | SOAT2 | O75908 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3963243 | 1.00 | NPC1 (0.47) | NPC1RAB9APAX8JAK2SOAT1 | |
| SCHEMBL4965873 | 0.88 | SOAT1 (0.46) | SOAT1ALDH1A1RIPK1HTR2A | |
| SCHEMBL4630764 | 0.81 | SOAT1 (0.46) | SOAT1ALDH1A1TP53HTR2A | |
| SCHEMBL9154366 | 0.81 | RIPK1 (0.57) | SOAT1RIPK1 | |
| SCHEMBL3965020 | 0.79 | TDP1 (0.41) | NPC1RAB9ARIPK1HTR2A | |
| SCHEMBL3963670 | 0.79 | YAP1 (0.53) | RAB9ASOAT1ALDH1A1RIPK1HTR2A | |
| SCHEMBL3964632 | 0.76 | RIPK1 (0.59) | RAB9AALDH1A1RIPK1 | |
| SCHEMBL3963598 | 0.74 | PPARA (0.42) | SOAT1 | |
| SCHEMBL3965232 | 0.74 | RAB9A (0.52) | NPC1RAB9AALDH1A1HTR2A | |
| SCHEMBL4961989 | 0.73 | ALDH1A1 (0.50) | SOAT1ALDH1A1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488844-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-02-10 | — | — | US | disclosed |
| US-20070244198-A1 | Carboxylic Derivatives | LI LANNA | 2007-10-18 | — | — | US | disclosed |
| US-20060258866-A1 | Carboxylic derivates | ASTRAZENECA AB, A SWEDEN CORPORATION | 2006-11-16 | — | — | US | disclosed |
| EP-1676833-A1 | Propionic acid derivatives useful in the treatment of lipid disorders | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| EP-1675820-A2 | PROPIONIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF LIPID DISORDERS | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| US-20050282822-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | disclosed |
| US-20050148656-A1 | 3-(amino-oxo(alkyl, alkyloxy and alkylthio)phenyl) propanoic and propenoic acid derivatives; peroxisome proliferator-activated receptors agonists; dyslipidemias with or without insulin resisitance and associated metabolic disorders (metabolic syndrome) including obesity, hypertension, type 2 diabetes | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | US | disclosed |
| WO-2004113270-A2 | PROPIONIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF LIPID DISORDERS | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244198-A1 | Carboxylic Derivatives | GPR119, CPT1A, PC | NPC1 59/4885RAB9A 2041/4885PAX8 4783/4885 |
| US-20050148656-A1 | 3-(amino-oxo(alkyl, alkyloxy and alkylthio)phenyl) propanoic and propenoic acid derivatives; peroxisome proliferator-activated receptors agonists; dyslipidemias with or without insulin resisitance and associated metabolic disorders (metabolic syndrome) including obesity, hypertension, type 2 diabetes | GPR119, PPARA, PPARG | NPC1 845/4885RAB9A 2433/4885PAX8 4258/4885 |
| US-20060258866-A1 | Carboxylic derivates | GPR119, PC, CPT1A | NPC1 130/4885RAB9A 2015/4885PAX8 4702/4885 |
| US-20050282822-A1 | Therapeutic agents | GPR119, LIPC, PNLIP | NPC1 14/4885RAB9A 1893/4885PAX8 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.